# Abbott Laboratories (ABT) — Earnings

ABT · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/abt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.31 |
| EPS estimate | $1.31 |
| EPS surprise | +0.00% |
| Revenue surprise | +0.58% |
| Revenue | $12.6B |
| Revenue estimate | $12.5B |
| Reported | Jul 16, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c829381e-8a6c-fdbe-3690-ca33893c78e0.html) |

Abbott reported Q2 2026 results on July 16, 2026. Earnings per share were $1.31, exactly matching the $1.31 estimate. Revenue was $12.6 billion against a $12.5 billion consensus, a 0.58% beat, and the highest quarterly figure in the table. Compared with Q2 2025, EPS rose about 4% from $1.26, while revenue rose about 14% from $11.1 billion.

Annual EPS fell from $5.34 in 2022 to $4.44 in 2023, then recovered to $4.67 in 2024 and $5.15 in 2025. The quarterly high in the table was $1.73 in Q1 2022 and the low was $0.98 in Q1 2024. The first half of 2026 adds up to $2.46 per share, about 5% more than a year earlier, while revenue grew faster, by about 11%. Over the last 20 quarters, Abbott beat the EPS estimate 17 times, missed twice and matched once. Surprises have narrowed. 2022 brought double-digit beats, while every result since the start of 2024 landed within 3.17% of the estimate.

Abbott reported Q3 between October 15 and October 20 in each of the past five years. That points to mid-October 2026 for the next report. It will show whether revenue growth keeps outpacing EPS growth.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 16, 2026 | $1.31 | $1.31 | 0.00% | $12.5B | $12.6B |
| Q1 2026 | Apr 16, 2026 | $1.14 | $1.15 | 0.46% | $11.0B | $11.2B |
| Q4 2025 | Jan 22, 2026 | $1.50 | $1.50 | 0.27% | $11.8B | $11.5B |
| Q3 2025 | Oct 15, 2025 | $1.30 | $1.30 | -0.21% | $11.4B | $11.4B |
| Q2 2025 | Jul 17, 2025 | $1.26 | $1.26 | 0.33% | $11.1B | $11.1B |
| Q1 2025 | Apr 16, 2025 | $1.07 | $1.09 | 1.66% | $10.4B | $10.4B |
| Q4 2024 | Jan 22, 2025 | $1.34 | $1.34 | -0.19% | $11.0B | $11.0B |
| Q3 2024 | Oct 16, 2024 | $1.20 | $1.21 | 0.65% | $10.6B | $10.6B |
| Q2 2024 | Jul 18, 2024 | $1.11 | $1.14 | 3.17% | $10.4B | $10.4B |
| Q1 2024 | Apr 17, 2024 | $0.96 | $0.98 | 2.62% | $9.9B | $10.0B |
| Q4 2023 | Jan 24, 2024 | $1.19 | $1.19 | 0.03% | $10.2B | $10.2B |
| Q3 2023 | Oct 18, 2023 | $1.10 | $1.14 | 3.57% | $9.8B | $10.1B |
| Q2 2023 | Jul 20, 2023 | $1.05 | $1.08 | 2.89% | $9.7B | $10.0B |
| Q1 2023 | Apr 19, 2023 | $0.99 | $1.03 | 4.01% | $9.7B | $9.7B |
| Q4 2022 | Jan 25, 2023 | $0.93 | $1.03 | 11.27% | $9.7B | $10.1B |
| Q3 2022 | Oct 19, 2022 | $0.94 | $1.15 | 21.93% | $9.6B | $10.4B |
| Q2 2022 | Jul 20, 2022 | $1.13 | $1.43 | 26.86% | $10.3B | $11.3B |
| Q1 2022 | Apr 20, 2022 | $1.47 | $1.73 | 18.09% | $11.0B | $11.9B |
| Q4 2021 | Jan 26, 2022 | $1.21 | $1.32 | 9.41% | $10.7B | $11.5B |
| Q3 2021 | Oct 20, 2021 | $0.94 | $1.40 | 48.16% | $9.6B | $10.9B |

## Frequently Asked Questions

### When did Abbott Laboratories (ABT) last report earnings?

Abbott Laboratories last reported on Jul 16, 2026, covering fiscal Q2 2026.

### Did ABT beat earnings estimates?

Abbott Laboratories reported EPS of $1.31 for Q2 2026, in line with the $1.31 consensus estimate.

### How much revenue did ABT report last quarter?

Abbott Laboratories reported $12.6B in revenue for Q2 2026, against a consensus estimate of $12.5B.

## Similar Stocks

- [ISRG](https://www.lighthorse.io/tickers/isrg) — Intuitive Surgical, Inc. - Common Stock
- [MDT](https://www.lighthorse.io/tickers/mdt) — Medtronic plc. Ordinary Shares
- [DXCM](https://www.lighthorse.io/tickers/dxcm) — DexCom, Inc. - Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [BSX](https://www.lighthorse.io/tickers/bsx) — Boston Scientific Corporation Common Stock
- [ITGR](https://www.lighthorse.io/tickers/itgr) — Integer Holdings Corporation Common Stock
- [ELV](https://www.lighthorse.io/tickers/elv) — Elevance Health, Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [BDX](https://www.lighthorse.io/tickers/bdx) — Becton, Dickinson and Company Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).